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The diagnosis of sarcoidosis in a patient living with HIV infection is an uncommon event and a challenge
for clinicians. Clinical manifestations are variable and fluctuating depending to adherence to ARV therapy
and to the level of CD4 count. We analyze here one chronic case in which sarcoidosis appeared clinically
two years after pulmonary tuberculosis. The course of the disease was influenced and prolonged by
frequent interruptions of antiretroviral therapy. Moreover the diagnosis and the decision to treat have
been delayed by the need of exclusion of other pathologies, principally tuberculosis reactivation/rein-
fection, other mycobacterial diseases, hematologic malignancies. We propose a simplified flowchart for
diagnosis and follow up of sarcoidosis, which may also be applied to patients with HIV infection.
Diagnosis of latent tuberculosis infection (LTBI) may be difficult in these patients, because the immu-
nological paradox of sarcoidosis. For this reason, following exclusion of active tuberculosis, we advise to
submit all sarcoidosis patients to IPT (isoniazid preventive therapy), when immunosuppressive therapy is
started.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sarcoidosis is a granulomatous multisystem chronic disease of
inflammatory origin. It is distributed worldwide, with a prevalence
of about 4.7e64 in 100,000 and incidence of 1.0e35.5/100,000 p.y.
Seventy % of patients are aged 25e45 years and in Europe and Japan
a second peak in incidence occurs in women aged more than 50
years. It is the second most common form of interstitial lung dis-
ease after idiopathic pulmonary fibrosis [10,18].
The diagnosis of sarcoidosis is made principally by exclusion of
other pathologies, together with histological evidence of typical
granulomas in tissues biopsy, mostly lung, skin and lymph nodes.
Similar to sarcoidosis is the combination of erythema nodosum,
bilateral hilar adenopathy and arthritis, called L€ofgren syndrome,
which diagnosis is clinical, it doesn't need biopsy and has a rela-
tively good prognosis [2,10,18].
Skin, liver and eyes are the most common localizations outsiderini).
Ltd. This is an open access article uthe lungs. This fact suggests that exposure to airborne antigens
(microbial antigens end/or pollutants) plays a role in triggering the
disease. Mycobacterial and propionibacterial antigens have been
identified in biopsies of patients affected by sarcoidosis [4,8].
Mycobacterial catalase-peroxidase was detected by immunoblot-
ting in 50% of tissue samples from patients with sarcoidosis.
Genomic fragments of Propionibacterium acnes and/or P. granulosus
were detected in almost all tissue samples of patients with
sarcoidosis coming from Europe (mainly England, Germany and
Italy) and Japan. Bacterial and mycobacterial antigens may persist
in macrophage phagosomes because they have membranes with
high lipid content and many of their glycoproteins are insoluble
and resistant to degradation.
A primary feature of sarcoidosis is the presence of CD4þ T-cells
that interact with antigen presenting cells to initiate the formation
and maintenance of granulomas. The triggering antigens favor
progressive accumulation and activation of selective T-cell clones.
These activated CD4þ cells differentiate into type 1 helper T (Th1)e
like cells and secrete predominantly interleukin-2 and interferon-g,
increase macrophage TNF-a production, and amplify the local
cellular immune responsewith granulomas formation. Granulomasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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epithelioid cells encircled by lymphocytes. Macrophages, chroni-
cally stimulated by cytokines, differentiate into epithelioid cells,
gain secretory and bactericidal capability, lose some phagocytic
capacity, and fuse to form multinucleated giant cells. In more
mature granulomas, fibroblasts and collagen encase the central
cluster of cells, and in some cases, sclerosis occurs, altering the
organ architecture and function and leading, for example, to
fibrosis of lung tissue. In Sarcoidosis is also present an “immuno-
logical paradox” [14]: despite extensive local inflammation, anergy
may develop, as indicated by suppression of the immune response
to cell antigens such as tuberculin. Amplification of CD25bright
FoxP3 regulatory T-cells, a subset of CD4þ T-lymphocytes, in active
sarcoidosis may account for this anergy by abolishing interleukin-2
production and strongly inhibiting T-cell proliferation, without
inhibiting the secretion of TNF-a and to a lesser extent IFN-g [10].
When patients infected by HIV have reduced circulating CD4þ T-
lymphocytes or dysfunctional T-cell mediated immunity, they
present a low incidence of sarcoidosis. As HIV has become a chronic
disease with immunity restoration made possible by antiretroviral
therapy, it is likely that sarcoidosis may increase in incidence. In
fact sarcoidosis diagnosis in HIV patients is associated with CD4þ T-
lymphocytes counts greater than 200 cells/ml [6,14]. Case reports of
coexistent sarcoidosis and HIV infection describes sarcoidosis as a
manifestation just occurring when the patient is restoring T-cell
mediated immunity, during the first 9 months (median) of antire-
troviral therapy [16]. Sarcoidosis in HIV patients seems in this way
to be a clinical manifestation of IRIS e immune reconstitution
syndrome, or a reactivation of previous disease.
We describe here one case of sarcoidosis in an HIV positive
patient followed at the National Institute of Infectious Diseases
“Lazzaro Spallanzani”e Rome during the period from 2003 to 2011.
2. Case presentation
CF, a 26-years-old man of North African origin, was hospitalized
for persistent cough on July 2003. Chest x-ray showed at this
moment bilateral hilar adenopathy and tenuous infiltration of the
upper right lobe. HRTC showed multiple irregular parenchymal
opacities of alveolar interstitial type at the upper lobes and bilateral
hilar enlargement.
Diagnosis of pulmonary TB was made after bronchoscopy on
July 2003, for positivity of M. tuberculosis DNA and RNA in bron-
choalveolar lavage fluid. Culture of sputum and BAL fluid were
negative. Tuberculin skin test was negative. Anti TB therapy was
started on July and continued for six months until January 2004.
HIV infection had been diagnosed just one month before this
hospitalization, on June 2003, with a CD4þ count of 371/mmc
(19.6%), HIVRNA 139,000 cp/ml (wild type) and HCV coinfection
(HCV type 1a). Antiretroviral therapy with (azt þ 3tc) þ nvp was
also started on June 2003. During the first year he attained a good
viro-immunological response, but later he became less compliant,
and on November 2004 he was lost to follow up.
On April 2006 he was readmitted at day service during a period
of jail detention: CD4þwere 374/mmc (26%), HIV viremia was 3055
cp/ml and HCV RNA titre was 3,097,802 cp/ml. ART therapy was
switched to tdf þ 3tcþ lpv/r. Chest x-ray showed pulmonary apical
bilateral infiltrates without pleural effusion, but the patient was
lost to follow up for a second time before doing further
investigations.
After two years, onMarch 2008, he was conducted to the service
for consultation: he was in good conditions, but since 2007 he was
developing chronic cutaneous maculopapular lesions at the right
arm. Adherence to ART therapy was suboptimal and he was highly
viremic, with 166,469 cp/ml of HIVRNA on July 2008. Therapy wasmodified to (tdf þ ftc) þ lpv/r. During the following year he
developed multiple symmetric lymphadenopathies (neck, axillae
and groin). Chest x-ray showed: bilateral fibronodular apical-
subclavian lesions with hilar enlargement and prominence of the
left second cardiac arch. CT-scan revealed mediastinal and intra-
abdominal periaortic severe adenopathy (4 cm diameter).
Biopsy of the forearm cutaneous lesions showed granulomatous
infiltration of sarcoid type without caseous necrosis. BAAR or fungi
were not detected by specific stains of the tissue.
He was hospitalized in another institution for dyspeptic symp-
toms on October 2009. Total body CT-scan showed enlarged intra-
abdominal lymph nodes (max 2.5 cm in diameter), hilar bilateral
adenopathy (3 cm in diam.) and apical pulmonary fibrosis with
reticulonodular infiltrates of lymphatic origin (galaxy sign). Biopsy
of an axillary lymph node showed foci of chronic granulomatous
epithelioid inflammation with giant multinucleated cells. No
mycobacteria spp, fungi or other parasites were demonstrated by
molecular or histological techniques. Bronchoscopy was also per-
formed with BAL and the research of malignant cells and myco-
bacteria spp was negative (MTB and atypical mycobacteria) by PCR
and culture. He was dismissed on November 2009 with the diag-
nosis of: “Chronic granulomatous lymphadenitis, Chronic Active
Hepatitis HCV-related, Duodenitis in patient with HIV infection C3,
Opioid addiction undergoing pharmacological therapy”.
Afterwards he continued ART therapy with better adherence,
but after few months he presented general malaise, weight loss,
persistent nausea and anorexia with emesis, increasing groin
adenopathy and was newly hospitalized for the clinical suspect of
lymphoma. Node biopsy showed: “Chronic granulomatous non
necrotising epithelioid gigantocellular lymphadenitis with
confluent foci as observed in sarcoidosis”. PCR for M. tuberculosis
DNA and for atypical mycobacteria from node sections was nega-
tive. Culture for M tuberculosis and other mycobacteria was also
negative. IGRA test (Quantiferon-TB test) was negative. Functional
respiratory tests were also performed: Walking test was normal,
Spirometry showed moderate-severe obstructive disease, with
reduction of CO diffusion. Salivary glands echography showed
parenchymal disomogeneity with ectasic ducta. Eye examination
was normal.
Steroid therapy was started on July 2010 with prednisone at the
dose of 1 mg/kg/die: after one month lymph nodes were consid-
erably reduced; the patient was gaining weight; he had neither
fever nor constitutional symptoms. He continued ART therapy with
(azt þ 3tc) þ lpv/r.
Corticosteroid therapy was continued for 6 months (including
one month of voluntary auto-suspension), but on March 2011 AST/
ALT values were increased (446/315 mU/ml). Liver biopsy was
decided, but the patient was definitely lost to follow up for personal
reasons.
3. Discussion
This clinical history has several critical points that we wish to
stress out. The first point is the diagnosis of pulmonary tubercu-
losis, which came quite at the same time of HIV infection diagnosis,
when the patient had about 300 CD4þ T-lymphocytes/mmc. TB
infection was demonstrated only by M. tuberculosis DNA and RNA
detection in BAL fluid by PCR. Microscopic examination and culture
of sputum and BAL fluid were negative. Radiological findings were
specific, with hilar bilateral enlargement and multiple irregular
opacities of alveolar interstitial type at the upper lobes. At this
moment a reactivation of a previous tubercular infection was
probably occurring, that is a common event in the evolution of
uncontrolled HIV infection.
Treatment of tubercular infection, together with anti-HIV
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several reasons, was not regular in assuming therapies. After anti-
TB therapy was completed (but not directly observed by our ser-
vice), ART therapy was interrupted and modified several times
during the following 3e5 years. This fact was coincident with the
development of generalized and important adenopathy, together
with the appearance of radiographic signs of interstitial lung
disease.
He underwent to repeated hospitalizations in order to exclude
hematologic malignancies, reactivation of tuberculosis, atypical
mycobacterial or fungal infections. Bronchoscopy with BAL fluid
examination for the research of infectious agents and malignant
cells was also performed, but without a differential cells count and
lymphocyte subset analysis. SACE test was never requested at
admission, maybe because it was prominent the suspect of malig-
nancy, evoked by conspicuous lymphadenopathy, and it was never
requested during the twelve months period of follow up. When
symptoms became too severe and diagnosis of sarcoidosis was
made by node biopsy, excluding infections and cancer, steroid
therapy was finally started. The patient achieved for the first time a
sustained virological response to HIV therapy, but, after 6months of
steroids, he had a flare of transaminases due to reactivation of
chronic HCV infection. Steroid therapywas stopped.We don't know
if sarcoidosis exacerbated after steroids withdrawal or if it relapsed
during the following years.
Below we propose a decisional “step-by-step” flowchart for
Sarcoidosis diagnosis (Fig. 1F) in order to facilitate this elusive
diagnosis. We want to point out that, in case of radiological signs of
lung granulomas, in HIV patients undergoing immune reconstitu-
tion (particularly during the first 9 months of HAART therapy) it is
essential to explore the possibility that the patient is affected by a
chronic granulomatous disease such as sarcoidosis.
Our patient was submitted to corticosteroid therapy with a
favorable evolution of adenopathy. Unfortunately, pulmonary
function tests were not repeated at follow up.1) Fatigue (77-71%)
2) Dyspnea (75-69%)
3) Arthralgia (61-46%)
4) Muscle pain (45-35%)
5) Persistent cough (32-
28%)
6) Eye problems (31-
25%)
7) Skin papular lesions, 
lupus pernio or 
erythema nodosum
(20-14%)
8) Palpable peripheral 
lymph nodes (15%)
•Chest-x-ray: bilateral hilar
infiltration
•CT scan: as supra with typ
•Flexible bronchoscopy: endobronchial ultrasound-guided tr
adenopathy 
•BALF: 20-50% lymphocytosis + CD4/CD8 >3.5,  microbiologi
diagnostic for alternative pathologies
•Biopsy of cutaneous papu
nodules for the research of
•Exclude pulmonary tuberc
IGRA negative, 3 sputum m
negative
•Biopsy of minor salivary gland if other tests failed
•Clinical assessment
Pulmonary Sarcoidosis
Scadding radiological staging 15: stage 1 (bilateral hilar aden
opacities predominant in upper zone); stage 3 (reticulonodul
opacities, small volume lungs, traction bronchiectasies, fibro
Pulmonary function tests: forced vital capacity, diffusion cap
Identifying extra pulmonary localizations
Hearth (2-5%): ECG, echocardiography, 24 h Holter monitorin
Eye (10-30%): systematic ophthalmologist examination, slit l
Liver (20-30%): liver function tests, echography and CT, biop
Nervous system (5%): CSF investigation, MRI, hormonal dos
Fig. 1. Flowchart for SarcoThe decision to start steroid therapy in a patient infected by HIV
is not simple, because clinicians may fear to arm the patient with
iatrogenic immunosuppression in case of LTBI. In our case, the fact
that anti TB therapy was completed before diagnosis of sarcoidosis
and that all microbiological examinations for M. tuberculosis and
atypical mycobacteria were negative, contributed to increase the
level of security for the patient when corticosteroid therapy was
requested.
In Fig. 2 we stress some relevant points extracted from literature
[2,3], useful for clinicians in the decision of starting immunosup-
pressive therapy and for the evaluation at follow up.
SACE determination has a limited diagnostic utility in sarcoid-
osis. Two recent population-based studies [9,17] compared the re-
sults of this test between patients with and without diagnosis of
sarcoidosis: Ungprasert et al. [17] confirmed a poor sensitivity
(41.4%) and specificity (89.9%), with a Positive Predictive Value
(PPV) of 25.4% and Negative Predictive Value (NPV) of 95%. Flood-
Page et al. [9], conversely, affirmed that high values of sACE
(>100 IU/L) have a Positive Predictive Value of 88%, arriving to 96%
if excluding patients with primary biliary cirrhosis and hypersen-
sitive pneumonitis. Since 1980 until now different Authors agree on
the fact that ACE test is of value as a serum marker for response to
therapy in those cases that were positive at diagnosis [3].
A lymphocyte differential count in BAL fluid 25% suggests
granulomatous lung disease, including sarcoidosis [13]. In a
selected population of sarcoidosis symptomatic patients, Danila
et al. [5] found 45 ± 19% lymphocytes in BAL fluid cells, but in pa-
tients empirically pretreated with systemic corticosteroids this
feature is less pronounced, with 39 ± 15% lymphocytes in the dif-
ferential count. In severe cases the number of neutrophils may also
be augmented [7].
The CD4/CD8 ratio in BAL fluid of patients with proven diagnosis
of sarcoidosis is highly variable. In 1997 Kantrow and colleagues
[12] published the results of CD4/CD8 ratio in BAL fluid of 86 pa-
tients: 42% of subjects showed a ratio greater than 4, and 12% had a adenopathy or diffuse micronodular parenchymal 
ical lymphatic distribution and “galaxy sign” 
ansbronchial biopsy of lung and mediastinal / hilar 
cal and cytological investigations negative or non 
lar lesions, peripheral lymph nodes or conjunctival 
 non caseating granulomas
ulosis and atypical mycobacteria : PPD test negative, 
icroscopy, DNA, RNA amplification and culture 
opathy - BHL); stage 2 (BHL and reticulonodular
ar opacities without adenopathy); stage 4 (reticular 
sis)   
acity of the lung carbon monoxide, 6-min walk distance 
g, BNP, MRI, perfusion scintigraphy, (18F-FDG) PET 
amp examination, fluorescein angiography  
sy 
e, EMG, temperature threshold testing, biopsy
•Mediastinoscopy 
idosis diagnosis [15].
• 50 % spontaneous resolution within 2 yrs (acute Sarcoidosis); chronic Sarcoidosis 
lasting ≥3-5 yrs
• Refractory Sarcoidosis: progressing despite treatment toward fibrosis (pulmonary and 
extrapulmonary), pulmonary hypertension, persistent disabling symptoms, impaired 
QoL
• 20-70% of patients need systemic therapy
• Indications for systemic therapy: cardiac disease; neurologic disease; eye disease 
not responding to topical therapy; hypercalcemia; progressive respiratory symptoms 
or demonstrated deterioration of lung function; widespread and progressing-
disfiguring skin lesions1,2
• Each 3-6 months: clinical examination, chest radiography, pulmonary function test, 
ECG and blood test (including calcium and creatinine blood concentrations, 24-hour 
urinary excretion of calcium )
• 37–74 % of treated patients have exacerbation / relapse when corticosteroids are 
tapered or discontinued
• Relapses occur 2-6 months after corticosteroids withdrawal ; they are rare after 3 
years without symptoms
Corticosteroids Cytotoxic drugs Cytokine modulators Antimicrobial drugs
Prednisone 2-3 
months, then 
tapering for 
other 3 months
Methotrexate
Azathioprine
Leflunomide
Cyclofosfamide
Mycophenolate mofetil
Pentoxifylline
Thalidomide
TNFα antagonist 
(infliximab)
Antimalarial drugs 
(hydroxychloroquine)
Tetracyclines
(minocycline, 
doxycycline)
Fig. 2. Therapy and follow up of Sarcoidosis.
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Even if it is recognized that lymphocytosis and an elevated CD4/
CD8 ratio in BAL fluid may strongly suggest sarcoidosis, it is so
necessary that the diagnosis is finally proven by biopsy of affected
tissues, specific clinical and radiological signs and by exclusion of
other pathologies [13].
In HIV patients with sarcoidosis CD4/CD8 ratio in BAL fluid is
even more variable, following the immunological condition at
diagnosis, the activity of the disease and the assumption of HAART.
In general, the ratio may be is less elevated than in non HIV pa-
tients, or normal [1,6,16].4. Conclusion
As often described in the literature the diagnosis of sarcoidosis
was delayed by the worry of clinicians to be in front of a case of
lymphoma or mycobacterial infection and, by the other side, by the
patient social instability. The decision to start steroid therapy was
also delayed because clinicians repeated several times the research
of active mycobacterial infection to be reassured to not put in arm
the patient. By the side of patient, the symptoms of sarcoidosis
(fatigue, cough and dyspnea) were probably negatively affecting
adherence to HAART therapy and, finally, they were directly and
proportionally linked to it by a causal relationship.
Clinical presentation and diagnosis of sarcoidosis in HIV-
positive patients is similar to that of other non co-infected pa-
tients, but it is particularly influenced by the fact that cellular im-
munity in HIV patients is highly variable, following ART therapy
start and/or discontinuation, with the possibility of crossing the
threshold of 200 CD4þ/mmc several times. The prominence of
adenopathy in our patient may be related to the fact that the in-
flammatory process was probably relapsing each time that HAART
was restarted. We don't know if this irregularity may facilitate re-
lapses or the evolution to pulmonary fibrosis of sarcoidosis.
The hypothesis of mycobacterial and/or bacterial antigens trig-
gering the pathogenic mechanism of sarcoidosis is also intriguing
[19]. Whenwe are evaluating a sarcoidosis patient co-infected withHIV, wemay also consider to be in front of a person at increased risk
to develop active tuberculosis during or after immunosuppressive
therapy, even if there is anergy to PPD test and/or IGRA tests are
negative at diagnosis, as this fact is explained by the immunological
paradox. For this reason it should be interesting to propose TB
prophylaxis to all HIV positive patients affected by sarcoidosis
when immunosuppressive therapy is considered. Further studies
are needed in order to evaluate the risk of developing active
tuberculosis in HIV patients with sarcoidosis after immunosup-
pressive therapy, if they were or not previously submitted to anti-
TB prophylaxis or therapy. We do not know if with iatrogenic
immunosuppressionwe can also induce active infection by atypical
mycobacteria. These questions may also be formulated regarding
others HIV patients in HAART, when they are affected by autoim-
mune disorders demanding immunosuppressive therapy [11].
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